Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

IL-15/IL-15Rα-targeted CRISPRa boosts NK cell effector function against HIV-infected cells.

Created on 06 Nov 2026

Authors

Samuel Brancazio, Tricia H Burdo, Liang Shan, Rafal Kaminski

Published in

Journal of leukocyte biology. Nov 05, 2026. Epub Nov 05, 2026.

Abstract

Like many other immune cell types, natural killer (NK) cells exhibit impaired functionality in people with HIV (PWH), limiting their ability to efficiently target and eliminate HIV-infected cells and contributing to the persistence of the HIV reservoir. Recently, adoptive NK cell therapy using activated or engineered NK cells has emerged as a promising immunotherapeutic strategy for cancer; however, its application to HIV remains in the early stages of development. NK cells primarily rely on interleukin-15 (IL-15) signaling for their development, survival, and maintenance, and dysregulated IL-15 signaling has been reported in PWH. We hypothesized that simultaneous enhancement of IL-15 and IL-15 receptor alpha (IL-15Rα) expression would improve NK cell effector function and promote clearance of HIV reservoir. Utilizing dCas9-VPR-mediated multiplex CRISPR activation (CRISPRa), we successfully upregulated both IL-15 and IL-15Rα expression in the same primary NK cells without altering the genomic sequence. CRISPRa-treated NK cells displayed increased IL-15 and IL-15Rα transcript levels, as measured by RT-qPCR and significantly elevated surface expression of IL-15Rα, as determined by flow cytometry. Enhanced IL-15/IL-15Rα expression increased NK cell metabolic activity and cytotoxicity against target K562 cells, a chronic myelogenous leukemia cell line, indicating improved effector function. Furthermore, in co-culture experiments using an HIV-positive T-cell line, IL-15/IL-15Rα-CRISPRa-treated NK cells demonstrated enhanced target cell elimination and increased secretion of IFN-γ. Together, these findings provide a proof of concept that multiplex CRISPRa can be used to enhance NK cell function, representing a novel strategy to improve persistence and therapeutic efficacy in HIV and other disease settings.

PMID:
42987219
Bibliographic data and abstract were imported from PubMed on 06 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement